Drug Profile
Research programme: endonuclease inhibitors - NERx Biosciences
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator NERx Biosciences
- Class Small molecules
- Mechanism of Action DNA repair inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in USA
- 27 Sep 2016 Early research in Cancer in USA before September 2016 (NERx Biosciences pipeline, September 2016)
- 27 Sep 2016 NERx Biosciences receives SBIR grant from National Cancer Institute for development of DNA repair endonuclease inhibitors in Cancer before September 2016 (NERx pipeline, September 2016)